Beckman bows out of Biosite bidding war as Inverness Medical Innovations muscles in
This article was originally published in Clinica
Executive Summary
Beckman Coulter has thrown in the towel in the fight for Biosite, announcing this week that it was not going to raise its $90 per share offer for the diagnostics manufacturer. The news comes days after rival Inverness Medical Innovations (IMI) sweetened its bid for Biosite from $90 to $92.50 per share.